Short-read Sequencing

Short-read Sequencing Market Outlook

The global short-read sequencing market is projected to reach approximately USD 9.50 billion by 2035, growing at a robust CAGR of around 11.5% during the forecast period of 2025 to 2035. This growth trajectory can be attributed to the increasing demand for personalized medicine, advancements in genomic research, and the rising prevalence of genetic disorders. Furthermore, technological improvements in sequencing methodologies and the consequent reduction in costs associated with sequencing are driving the adoption of short-read sequencing techniques. The growing emphasis on precision medicine and the need for rapid diagnostics, particularly in clinical settings, are also contributing to the expansion of this market. Additionally, strategic collaborations and partnerships among key stakeholders are enhancing the accessibility and application of short-read sequencing technologies across multiple sectors.

Growth Factor of the Market

The growth of the short-read sequencing market is largely influenced by several key factors that enhance its adoption across various sectors. Firstly, the rapid advancements in sequencing technologies have rendered the process faster, more accurate, and cost-effective, thereby encouraging more institutions and organizations to invest in this area. Secondly, the increasing prevalence of genetic disorders and infectious diseases is propelling the demand for efficient diagnostic tools, with short-read sequencing emerging as a vital solution. Additionally, the rising trend toward precision medicine is urging healthcare providers to utilize genomic data for tailored treatments, further boosting the market. Moreover, the ongoing research initiatives and funding from government bodies and private sectors aimed at enhancing genomic studies play a significant role in the market’s growth. Lastly, the versatility of short-read sequencing applications across multiple fields, including clinical diagnostics, drug discovery, and agriculture, positions it favorably for sustained growth in the future.

Key Highlights of the Market

• Projected market growth to USD 9.50 billion by 2035 with a CAGR of 11.5% from 2025 to 2035.
• Technological advancements are significantly lowering costs and increasing accessibility.
• Increasing prevalence of genetic disorders and infectious diseases driving demand.
• Growth in personalized medicine and tailored treatment options for patients.
• Versatile applications across various sectors such as healthcare, agriculture, and research.

By Product Type

Sequencing Platforms:

Sequencing platforms are a pivotal component of the short-read sequencing market, encompassing the instruments and systems designed to perform sequencing tasks. These platforms have evolved significantly, with advancements in technology leading to increased throughput, accuracy, and scalability. Notable examples include the Illumina sequencing systems that are widely utilized due to their high accuracy and cost-effectiveness. As demand for high-volume sequencing rises, companies are focused on enhancing platform capabilities to support extensive genomic studies, especially in clinical diagnostics and research applications. The growth of sequencing platforms is further supported by the expanding accessibility of these technologies to research institutions and hospitals, contributing to the overall market growth.

Sequencing Reagents:

Sequencing reagents play a significant role in the short-read sequencing process, encompassing the chemicals and compounds used to facilitate the sequencing reactions. The market for sequencing reagents is witnessing substantial growth due to the rising volume of sequencing applications across various fields. These reagents are essential for ensuring the accuracy and efficiency of sequencing results, and as such, their demand is intrinsically linked to the growth of sequencing platforms. Moreover, continuous innovations and enhancements in reagent formulations are driving their adoption, especially in clinical diagnostics where precision and reliability are paramount. Manufacturers are increasingly focusing on developing high-quality reagents that minimize errors and improve sequencing outcomes, thereby fostering growth in this segment.

Sequencing Services:

Sequencing services represent a crucial segment of the short-read sequencing market, providing end-users with outsourced solutions for their sequencing needs. These services are especially valuable for organizations that may not have access to advanced sequencing technologies or expertise in-house. The growth of sequencing services is driven by the increasing demand for genomic analysis in diverse applications, including clinical diagnostics, research, and drug discovery. Service providers are expanding their offerings to include comprehensive analysis and interpretation services, thereby enhancing value for their clients. Additionally, the rise of contract research organizations (CROs) that specialize in genomic services is facilitating more streamlined access to sequencing technologies, contributing to market growth.

By Application

Clinical Diagnostics:

Clinical diagnostics is one of the largest applications for short-read sequencing, as it enables the identification of genetic mutations and variations associated with diseases. This application is crucial for the early diagnosis of hereditary disorders, cancer, and infectious diseases, thus playing a vital role in improving patient outcomes. The integration of short-read sequencing into routine clinical practice is on the rise, driven by the increasing emphasis on personalized medicine and tailored treatment plans. Furthermore, regulatory approvals for genomic tests and the growing acceptance of sequencing as a standard diagnostic tool are propelling its adoption in clinical settings. The ability to analyze large volumes of genomic data quickly and accurately is significantly enhancing the capabilities of healthcare providers in disease management and prevention.

Drug Discovery:

The drug discovery application of short-read sequencing is gaining significant traction, as researchers leverage genomic data to develop new therapeutics and improve existing drug formulations. By facilitating a better understanding of genetic factors influencing drug response and efficacy, short-read sequencing is revolutionizing the traditional drug discovery process. Additionally, the integration of sequencing data with other omics technologies is enabling a more comprehensive approach to drug development, reducing the time and cost involved in bringing new drugs to market. As pharmaceutical companies increasingly prioritize the development of targeted therapies and personalized medicine, the demand for short-read sequencing in the drug discovery phase is expected to rise significantly.

Agriculture:

In agriculture, short-read sequencing is being harnessed for crop improvement, pest resistance, and the study of plant genomes. This application is particularly valuable as it allows for the identification of genetic traits that can enhance yield, resilience, and nutritional value. As the global population continues to rise, the demand for efficient and sustainable agricultural practices is driving the adoption of genomics in farming. By utilizing short-read sequencing, agricultural researchers can develop genetically modified crops and improve breeding programs, addressing food security challenges in the process. The increasing investment in agricultural biotechnology and the growing importance of sustainable farming practices are expected to bolster this application segment in the coming years.

Animal Research:

Animal research is another important area benefiting from short-read sequencing, as it aids in the study of genetics and diseases in various animal species. This application is particularly relevant in veterinary medicine, where understanding genetic predispositions can improve animal health and welfare. The ability to sequence genomes of different species allows researchers to draw parallels between human and animal genetics, facilitating advancements in comparative medicine. Moreover, short-read sequencing is being employed in conservation efforts to monitor genetic diversity among endangered species. As research initiatives aimed at understanding animal genomics continue to grow, the demand for sequencing technologies in this field is anticipated to increase substantially.

Microbiology:

Microbiology is a rapidly advancing field that is increasingly utilizing short-read sequencing for the identification and characterization of microbial organisms. The ability to rapidly sequence and analyze microbial genomes has significant implications for public health, food safety, and environmental monitoring. Short-read sequencing offers insights into microbial diversity, pathogenicity, and antibiotic resistance, which are critical for developing effective treatment and prevention strategies. Additionally, the ongoing global health challenges, including infectious disease outbreaks, underscore the importance of genomic surveillance through sequencing. As researchers seek to understand complex microbial communities and their interactions, the application of short-read sequencing in microbiology is set to expand further, driving innovation and discovery.

By End User

Hospitals:

Hospitals are increasingly adopting short-read sequencing technologies to enhance their diagnostic capabilities, particularly in genomic medicine. By integrating sequencing into clinical workflows, hospitals can provide more accurate diagnoses and treatment plans based on individual genetic profiles. The growing prevalence of hereditary diseases and cancers has led to a greater demand for genomic testing in hospitals, thereby driving the adoption of short-read sequencing. Furthermore, hospitals are utilizing sequencing for prenatal testing and infectious disease identification, significantly improving patient care. As hospitals continue to invest in advanced technologies for precision medicine, the role of short-read sequencing in enhancing clinical outcomes is expected to expand further.

Pharmaceutical & Biotechnology Companies:

Pharmaceutical and biotechnology companies are at the forefront of adopting short-read sequencing technologies for drug development and research purposes. These companies leverage sequencing to identify genetic biomarkers, understand disease mechanisms, and develop targeted therapies. The ability to generate high-quality genomic data quickly is essential for advancing drug discovery and accelerating the development of personalized medicine. Additionally, as the regulatory landscape evolves to support genomic-based therapies, pharmaceutical companies are increasingly integrating short-read sequencing into their research pipelines. The growing collaboration between biotech firms and research institutions is also driving innovations in this segment, further enhancing the role of sequencing in drug development.

Research Institutes:

Research institutes are major users of short-read sequencing technologies, utilizing them for a wide range of genomic studies. This segment encompasses academic research organizations, government laboratories, and non-profit research institutions engaged in cutting-edge studies aimed at understanding genetic diseases and evolutionary biology. The ability to conduct high-throughput sequencing has revolutionized research methodologies, enabling scientists to explore complex genomic questions with unprecedented depth and accuracy. Research institutes are also instrumental in developing new sequencing techniques and methodologies, contributing to advancements in the field. As funding for genomic research continues to grow, the demand for short-read sequencing in research settings is anticipated to remain strong.

Contract Research Organizations:

Contract research organizations (CROs) are increasingly utilizing short-read sequencing technologies to provide outsourcing solutions for pharmaceutical and biotechnology companies. These organizations offer a range of services, including study design, data generation, and analysis, enabling clients to accelerate their research and development processes. The flexibility and scalability of short-read sequencing make it an attractive option for CROs, allowing them to meet diverse client needs. Additionally, as companies seek to reduce operational costs and improve efficiency, the demand for CRO services that incorporate genomic technologies is on the rise. The growing trend towards outsourcing in the biopharmaceutical industry is further propelling the adoption of short-read sequencing within CROs.

Diagnostic Centers:

Diagnostic centers are increasingly incorporating short-read sequencing into their testing offerings to enhance the accuracy and speed of diagnoses. These centers specialize in providing genetic testing services for a variety of conditions, including rare diseases, cancers, and infectious diseases. The ability to perform comprehensive genomic analyses allows diagnostic centers to offer personalized insights and treatment recommendations for patients. As the demand for genetic testing continues to grow, driven by consumer awareness and advances in technology, the role of diagnostic centers in utilizing short-read sequencing is becoming more prominent. The integration of sequencing services into routine diagnostic workflows is expected to enhance the quality of care provided to patients.

By Technology

Sequencing by Synthesis:

Sequencing by synthesis (SBS) is one of the most widely used technologies in the short-read sequencing market, known for its high accuracy and throughput capabilities. This method involves the incorporation of fluorescently labeled nucleotides, allowing for the detection of incorporated bases during DNA synthesis. The SBS platform has been instrumental in numerous genomic projects, including the Human Genome Project, due to its ability to generate massive amounts of data efficiently. Companies like Illumina have pioneered SBS technology, making it a preferred choice for various applications, including clinical diagnostics and research. As the demand for high-accuracy sequencing continues to rise, SBS technology is expected to maintain a significant presence in the market.

Sequencing by Ligation:

Sequencing by ligation is another technology segment within the short-read sequencing market that utilizes oligonucleotide probes to identify nucleotides. This method is characterized by its unique strategy of ligating fluorescently labeled probes to the target DNA, enhancing accuracy and reducing errors associated with sequencing. The ligation-based method is particularly advantageous for applications requiring high specificity, such as in the detection of single nucleotide polymorphisms (SNPs). Companies that specialize in this technology are continually innovating to improve its efficiency and reduce costs, making it an appealing option in the market. As researchers seek alternative methodologies for precise genomic analysis, sequencing by ligation is expected to gain traction.

Pyrosequencing:

Pyrosequencing is a sequencing technology that enables real-time monitoring of DNA synthesis through the detection of released pyrophosphate during nucleotide incorporation. This method offers several advantages, including faster turnaround times and the ability to perform sequencing reactions in a single step. Pyrosequencing is particularly well-suited for applications such as mutation detection and microbial typing, where rapid results are critical. While it may not have the same throughput as some other sequencing methods, its unique capabilities make it a valuable tool for specific genomic applications. As the demand for efficient sequencing solutions continues to grow, pyrosequencing remains a relevant player in the short-read sequencing market.

Ion Semiconductor Sequencing:

Ion semiconductor sequencing is an innovative technology that leverages semiconductor chips to detect changes in pH as nucleotides are added during DNA synthesis. This method is known for its rapid sequencing capabilities and relatively low cost, making it an attractive option for various applications, including clinical diagnostics and research. The ability to generate data in real time significantly enhances the efficiency of sequencing processes. Companies specializing in ion semiconductor sequencing are focusing on improving the accuracy and scalability of this technology, thus broadening its applicability. As researchers and clinicians seek faster and more affordable sequencing solutions, ion semiconductor sequencing is expected to play an increasingly important role in the market.

Single-Molecule Real-Time Sequencing:

Single-molecule real-time (SMRT) sequencing is a cutting-edge technology that allows for the direct observation of DNA synthesis in real-time. This method provides unparalleled accuracy and the ability to read long contiguous sequences of DNA, making it particularly valuable for applications such as complex genome assembly and structural variant detection. The capacity to analyze individual molecules without the need for amplification significantly reduces errors, enhancing the reliability of results. As the need for comprehensive genomic data increases, SMRT sequencing is gaining traction among researchers and clinical laboratories. The ongoing developments in this technology are expected to further enhance its adoption and utility in the short-read sequencing market.

By Region

The North American region holds a dominant position in the short-read sequencing market, accounting for approximately 40% of the global market share. This dominance is attributed to the presence of advanced healthcare infrastructure, high levels of research funding, and a robust biotechnology sector. The United States, in particular, has witnessed significant investments in genomics and precision medicine, fostering an environment conducive to the growth of sequencing technologies. With major players headquartered in this region, the ongoing advancements in sequencing platforms and reagents further contribute to market expansion. The North American market is projected to grow at a CAGR of 12% from 2025 to 2035, driven by continuous innovations and increasing adoption of sequencing in clinical applications.

Europe is the second-largest market for short-read sequencing, accounting for around 30% of the global market share. The region is characterized by a strong emphasis on genomic research and healthcare advancements, supported by substantial government funding and collaborative initiatives among research institutions. The integration of sequencing technologies into clinical practice is also on the rise, with many countries adopting genomics as a standard diagnostic tool. Growth opportunities in this region are bolstered by increasing efforts to enhance personalized medicine and the focus on combating genetic diseases. As the European market continues to evolve, it is expected to grow steadily due to the rising demand for genomic testing and sequencing services.

Opportunities

One significant opportunity in the short-read sequencing market lies in the burgeoning field of personalized medicine. The shift towards tailored healthcare solutions is driving the demand for genomic data that can inform individualized treatment plans based on a patient's unique genetic makeup. As more healthcare providers recognize the value of genomics in improving patient outcomes, the need for efficient and accurate sequencing technologies becomes increasingly critical. This presents an opportunity for companies involved in short-read sequencing to develop targeted solutions that cater to the specific needs of clinicians and patients. By investing in research and development aimed at enhancing sequencing capabilities, companies can position themselves advantageously in this rapidly evolving market.

Another burgeoning opportunity is the integration of artificial intelligence and machine learning into genomic analysis. The vast amounts of data generated through short-read sequencing present challenges in data interpretation and analysis, creating a need for innovative solutions that can streamline these processes. By leveraging AI and machine learning technologies, companies can develop advanced bioinformatics tools that enhance data analysis, enabling more robust insights and faster turnaround times for genomic studies. This integration not only improves the efficiency of genomic research but also opens avenues for new application areas, such as population genomics and epidemiological studies. As the demand for sophisticated data analysis continues to grow, this intersection of technology and genomics represents a promising opportunity for market participants.

Threats

One of the significant threats facing the short-read sequencing market is the rapid pace of technological advancements, which can lead to increased competition among companies in the sector. As new and innovative sequencing technologies emerge, established players may find it challenging to keep up with evolving customer demands and preferences. This heightened competition can exert pressure on pricing and profit margins, potentially leading to market share erosion for existing companies. Additionally, as new entrants introduce disruptive technologies or methodologies, established companies may need to invest heavily in research and development to maintain their competitive edge. The need for continuous innovation is imperative, and failure to adapt swiftly to changes in the market could jeopardize the sustainability of businesses operating in the sequencing industry.

Another challenge facing the short-read sequencing market is the regulatory landscape governing genetic testing and sequencing technologies. As governments and regulatory bodies implement stricter guidelines and standards for genomic testing, companies may encounter hurdles in obtaining necessary approvals for their products and services. Navigating the regulatory environment can be time-consuming and costly, potentially delaying the introduction of new technologies to the market. Additionally, discrepancies in regulations across different regions may create complexities for companies seeking to expand their global presence. As the market continues to grow, aligning with evolving regulatory requirements will be crucial for ensuring compliance and maintaining consumer trust.

Competitor Outlook

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Pacific Biosciences of California, Inc.
• BGI Group
• Oxford Nanopore Technologies Limited
• Roche Sequencing Solutions
• Qiagen N.V.
• Agilent Technologies, Inc.
• Macrogen, Inc.
• Zymo Research Corporation
• Genomatix Software GmbH
• MedGenome Labs Limited
• Stratagene (a part of Agilent Technologies)
• Novogene Corporation
• Epic Sciences, Inc.

The competitive landscape of the short-read sequencing market is characterized by a dynamic interplay of established players and new entrants vying for market share. Major companies like Illumina and Thermo Fisher Scientific dominate the market with their extensive product portfolios and advanced sequencing platforms. These companies continually invest in research and development to introduce innovative solutions that cater to the growing demand for genomic data across various applications. The competitive strategy employed by these companies often involves strategic partnerships and collaborations with research institutions and healthcare providers to enhance their offerings and improve customer satisfaction. Additionally, the increasing emphasis on personalized medicine and precision health solutions is shaping the competitive dynamics within the market, with companies differentiating themselves based on technological advancements and service offerings.

Illumina, Inc. is a frontrunner in the short-read sequencing market, recognized for its pioneering contributions to sequencing technologies. The company's flagship product line, the NovaSeq platform, is widely utilized in both research and clinical settings, offering high-throughput sequencing capabilities with exceptional accuracy. Illumina's commitment to innovation is evident in its continuous improvements and upgrades to sequencing technologies, ensuring that clients have access to the latest advancements. Additionally, the company's focus on strategic partnerships with academic institutions and healthcare organizations further solidifies its leadership position in the market. As the demand for genomic data continues to grow, Illumina is well-positioned to capitalize on emerging opportunities and expand its market presence.

Thermo Fisher Scientific Inc. is another key player in the short-read sequencing market, providing a comprehensive range of sequencing solutions through its Ion Torrent platform. The company's innovative approach to semiconductor sequencing technology has made it a preferred choice for various applications, including clinical diagnostics and research. With a strong emphasis on customer support and service, Thermo Fisher is dedicated to enhancing the overall user experience, which has contributed to its favorable market positioning. The company's diverse portfolio also includes reagents, consumables, and bioinformatics tools, enabling it to cater to a wide array of customer needs. As Thermo Fisher continues to expand its product offerings and improve its technologies, it remains a formidable competitor in the short-read sequencing market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 BGI Group
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Qiagen N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Illumina, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Macrogen, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Epic Sciences, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Novogene Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 MedGenome Labs Limited
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Genomatix Software GmbH
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Zymo Research Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Agilent Technologies, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Roche Sequencing Solutions
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Oxford Nanopore Technologies Limited
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Pacific Biosciences of California, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Stratagene (a part of Agilent Technologies)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Short-read Sequencing Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Pharmaceutical & Biotechnology Companies
    • 6.1.3 Research Institutes
    • 6.1.4 Contract Research Organizations
    • 6.1.5 Diagnostic Centers
  • 6.2 Short-read Sequencing Market, By Technology
    • 6.2.1 Sequencing by Synthesis
    • 6.2.2 Sequencing by Ligation
    • 6.2.3 Pyrosequencing
    • 6.2.4 Ion Semiconductor Sequencing
    • 6.2.5 Single-Molecule Real-Time Sequencing
  • 6.3 Short-read Sequencing Market, By Application
    • 6.3.1 Clinical Diagnostics
    • 6.3.2 Drug Discovery
    • 6.3.3 Agriculture
    • 6.3.4 Animal Research
    • 6.3.5 Microbiology
  • 6.4 Short-read Sequencing Market, By Product Type
    • 6.4.1 Sequencing Platforms
    • 6.4.2 Sequencing Reagents
    • 6.4.3 Sequencing Services

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Short-read Sequencing Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Short-read Sequencing market is categorized based on

By Product Type

• Sequencing Platforms
• Sequencing Reagents
• Sequencing Services

By Application

• Clinical Diagnostics
• Drug Discovery
• Agriculture
• Animal Research
• Microbiology

By End User

• Hospitals
• Pharmaceutical & Biotechnology Companies
• Research Institutes
• Contract Research Organizations
• Diagnostic Centers

By Technology

• Sequencing by Synthesis
• Sequencing by Ligation
• Pyrosequencing
• Ion Semiconductor Sequencing
• Single-Molecule Real-Time Sequencing

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Pacific Biosciences of California, Inc.
• BGI Group
• Oxford Nanopore Technologies Limited
• Roche Sequencing Solutions
• Qiagen N.V.
• Agilent Technologies, Inc.
• Macrogen, Inc.
• Zymo Research Corporation
• Genomatix Software GmbH
• MedGenome Labs Limited
• Stratagene (a part of Agilent Technologies)
• Novogene Corporation
• Epic Sciences, Inc.